Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I pharmacokinetic study of JHL1149 in China

Trial Profile

A Phase I pharmacokinetic study of JHL1149 in China

Planning
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 16 Oct 2018 National Medical Products Administration of the PRC (NMPA) has approved Phase I and Phase III Clinical Trial Application for JHL1149.
    • 16 Apr 2018 According to a JHL Biotech media release, the China Food and Drug Administration (CFDA) has accepted for review JHL's Clinical Trial Application for a proposed bevacizumab biosimilar, JHL1149, to treat cancer.
    • 16 Apr 2018 According to a JHL Biotech media release, the data from this and other trials will support the global registration and commercialization of JHL1149.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top